HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Genscript Biotech (1548.HK) 22H1 - The Outlook and the Risks Behind

Genscript Biotech (1548.HK) - Inadequate Cognition Will Lead to Bad Investment Decisions

China Healthcare Weekly (Feb.17) - CXO Vs Pharma, Medical Insurance Account Reform, Time to Reflect

Pre-IPO Dingdang Health Technology - The Future Looks Challenging

Pre-IPO Beijing Continent Pharmaceuticals - The Orphan Drug Pioneer Needs to Expand Overseas

Pre-IPO Scivita Medical Technology - The Industry, the Business, and the Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<ul>
<li>As one of the few companies in the world that could provide one-stop solutions including all major medical devices used in non-vascular interventional surgery, Innovex’s outlook is promising.</li>
<li>About 30% overseas revenue indicates that the Company’s internationalization is on track, which could help to "hedge" negative domestic policy risks.</li>
<li>In terms of the valuation, Innovex’s valuation should be higher than Scivita but lower than Aohua. However, Innovex has the potential to surpass Aohua in the future.</li>
</ul>


As one of the few companies in the world that could provide one-stop solutions including all major medical devices used in non-vascular interventional surgery, Innovex’s outlook is promising.
About 30% overseas revenue indicates that the Company’s internationalization is on track, which could help to "hedge" negative domestic policy risks.
In terms of the valuation, Innovex’s valuation should be higher than Scivita but lower than Aohua. However, Innovex has the potential to surpass Aohua in the future.


Pre-IPO Innovex Medical - A Comprehensive Product Portfolio Underpins Future Growth Prospects